

# HEALTHCARE MONTHLY

OCTOBER 2021

*Our healthcare team architects market-defining outcomes for some of the world's most innovative medical device, life science, diagnostics, healthcare services and pharmaceutical companies*

BioTech / Pharma

Healthcare Services

Life Sciences / Diagnostics


Medical Devices

## HEADLINE TRANSACTIONS


	TARGET	ACQUIROR	ACQUISITION SYNOPSISIS
Medical Devices			<ul style="list-style-type: none"> <li>GE Healthcare, a division of General Electric (NYSE:GE), entered into a definitive agreement to acquire BK Medical Holding Company</li> <li>BK Medical manufactures noninvasive, intraoperative ultrasound imaging equipment</li> <li>GE Healthcare provides medical imaging, monitoring, biomanufacturing and cell and gene therapy technologies</li> <li>Total Consideration: \$1.5 billion in cash</li> </ul>
			<ul style="list-style-type: none"> <li>Advent International entered into a definitive agreement to acquire Swedish Orphan Biovitrum (OM:SOBI)</li> <li>Swedish Orphan Biovitrum develops and manufactures pharmaceuticals in the areas of hematology, immunology, and genetic and metabolic diseases</li> <li>Advent International is a multinational private equity firm with more than \$75 billion of assets under management</li> <li>Total Consideration: \$8 billion in cash</li> <li>Implied Enterprise Value: 5.6x LTM Revenue, 14.4x LTM EBITDA (35% premium)</li> </ul>
BioTech / Pharma			<ul style="list-style-type: none"> <li>Merck (NYSE:MRK) entered into a definitive agreement to acquire Acceleron Pharma (NasdaqGM:XLRN)</li> <li>Acceleron Pharma develops pharmaceutical drugs utilizing the transforming growth factor (TGF)-beta superfamily of proteins for pulmonary and hematologic diseases</li> <li>Merck manufactures and distributes vaccines, prescription products, oncology products, consumer products, animal health products and biologic therapies for customers worldwide</li> <li>Total Consideration: \$11.5 billion in cash</li> <li>Implied Enterprise Value: 108.7x LTM Revenue (34% premium)</li> </ul>
			<ul style="list-style-type: none"> <li>Grifols (BME:GRF) entered into a definitive agreement to acquire Biotest Aktiengesellschaft (XTRA:BI03)</li> <li>Biotest develops and manufactures pharmaceutical products in the areas of hematology, clinical immunology, and intensive care medicine</li> <li>Grifols is an industry leader that produces plasma-derived and transfusion medicines</li> <li>Total Consideration: \$1.9 billion in cash</li> <li>Implied Enterprise Value: 3.7x LTM Revenue (22% Premium)</li> </ul>

# HEALTHCARE GROWTH & VALUATION TRENDS


Enterprise Value / LTM Revenue




Enterprise Value / LTM EBITDA



LTM Revenue Growth




LTM Gross and EBITDA Margins\*



\*EBITDA Margins shown as the gray line.

LTM Stock Price Index



115% BioTech / Pharma    106% Health Services    131% Life Sci / Diagnostics    122% Medical Devices    127% S&P 500 Index

# SELECTED HEALTHCARE TRANSACTIONS

Target	Acquiror	BioTech / Pharma Transactions
HRA Pharma	Perrigo (NYSE:PRGO)	HRA Pharma offers a portfolio of OTC self-care brands, primarily in blister care, women's health and scar care Total consideration: \$2.1 billion in cash
First Wave Bio, Inc.	AzurRx BioPharma, Inc. (nka:First Wave BioPharma, Inc.) (NasdaqCM:FWBI)	First Wave Bio develops new, gut-targeted, small molecule treatments for auto-immune inflammatory bowel diseases and various other diseases Total consideration: \$229 million in cash and stock
Aspire Pharma Limited	H.I.G. Capital	Aspire Pharma develops a variety of niche generic and specialty pharmaceutical products for use primarily in the United Kingdom

Target	Acquiror	Life Sci / Diagnostics Transactions
Prenetics Global Limited	Artisan Acquisition Corp. (NasdaqCM:ARTA)	Prenetics is the leading genomic and diagnostic testing provider in the United Kingdom and Hong Kong Total consideration: \$459 million, representing an enterprise value of \$1.25 billion
Agena Bioscience, Inc.	Mesa Laboratories, Inc. (NasdaqGS:MLAB)	Agena provides reagents, assay development services, and software to the biopharmaceutical industry as well as high-throughput genotyping and mutation profiling through its MassARRAY system Total consideration: \$300 million in stock
Avitide, Inc.	Repligen Corporation (NasdaqGS:RGEN)	Avitide manufactures and supplies molecule-specific affinity purification solutions for the biopharmaceutical industry Total consideration: \$75 million in cash and \$75 million in stock-based earnout

Target	Acquiror	Health Services Transactions
Generations Home Health, LLC	LHC Group, Inc. (NasdaqGS:LHGC)	Generations Home Health provides in-home medical care across Virginia for illness, injury and chronic diseases
Renew Consulting	Pathways Health and Community Support (Atar Capital)	Renew Consulting is an Oregon-based residential behavioral health company providing customized support for individuals with developmental disabilities and mental health needs
Chesnut Hill Hospital	Trinity Health Mid-Atlantic	Chesnut Hill Hospital is a primary care provider located in Philadelphia, Pennsylvania; more than a dozen urgent care facilities were also included in the transaction

Target	Acquiror	Medical Device Transactions
Itamar Medical (TASE:ITMR)	ZOLL Medical Corporation	Itamar develops non-invasive medical devices and solutions for the diagnosis and treatment of respiratory sleep disorders Total Consideration: \$538 million in cash (50% premium)
Devoro Medical, Inc.	Boston Scientific Corporation (NYSE:BSX)	Devoro Medical produces a thrombectomy medical device intended to restore blood flow Total consideration: \$269 million in cash and \$67 million in potential earnout
Allied 100, LLC	Cardio Partners, Inc.	Allied 100 distributes automated external defibrillator (AED) and ancillary parts and accessories Total consideration: \$290 million in cash

## Selected TM Capital Healthcare Experience



HAS BEEN ACQUIRED BY





HAS RECEIVED AN INVESTMENT FROM



\$64,400,000  
SERIES C EQUITY



## TM Capital's Healthcare Industry Contacts



**James McLaren**  
Managing Director  
jmclaren@tmcapital.com  
212.809.1414



**Michael Goldman**  
Managing Director  
mgoldman@tmcapital.com  
212.809.1419



**Paul Smolevitz**  
Managing Director  
psmolevitz@tmcapital.com  
212.809.1416



**John Dean**  
Principal  
jdean@tmcapital.com  
404.995.6234



**Steve Hunter**  
Managing Director, Sponsor Coverage  
shunter@tmcapital.com  
404.995.6232